0000000000733466

AUTHOR

Fabian Lang

showing 2 related works from this author

Challenges of patients with myeloproliferative neoplasms (MPN) in times of COVID: first results from a patient survey by the German Study Group for M…

2021

AdultMaleCancer Researchmedicine.medical_specialty2019-20 coronavirus outbreakAdolescentCoronavirus disease 2019 (COVID-19)Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)MEDLINEGermanYoung AdultGermanySurveys and QuestionnairesInternal medicineCorrespondencemedicineHumansAgedAged 80 and overMyeloproliferative DisordersSARS-CoV-2business.industryCOVID-19HematologyMiddle AgedPrognosisTelemedicinelanguage.human_languageOncologylanguageFemalePatient surveybusinessFollow-Up StudiesLeukemia Research
researchProduct

Sorafenib maintenance after allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia with FLT3-internal tandem duplication mutat…

2020

PURPOSE Despite undergoing allogeneic hematopoietic stem cell transplantation (HCT), patients with acute myeloid leukemia (AML) with internal tandem duplication mutation in the FMS-like tyrosine kinase 3 gene ( FLT3-ITD) have a poor prognosis, frequently relapse, and die as a result of AML. It is currently unknown whether a maintenance therapy using FLT3 inhibitors, such as the multitargeted tyrosine kinase inhibitor sorafenib, improves outcome after HCT. PATIENTS AND METHODS In a randomized, placebo-controlled, double-blind phase II trial (SORMAIN; German Clinical Trials Register: DRKS00000591), 83 adult patients with FLT3-ITD–positive AML in complete hematologic remission after HCT were r…

SorafenibFLT3 Internal Tandem DuplicationCancer ResearchMyeloidbusiness.industrymedicine.medical_treatmentMyeloid leukemiaHematopoietic stem cell transplantationmedicine.diseaseTransplantationLeukemiamedicine.anatomical_structureOncologyhemic and lymphatic diseasesmedicineCancer researchNeoplasmbusinessmedicine.drug
researchProduct